Abstract Body

Background: Currently, only one boosted PI is approved for use in infants: lopinavir/ritonavir (LPV/r). The LPV/r formulation is not ideal for infants and children living in resource-poor settings, as it is poorly tolerated, needs refrigeration, contains large amounts of undesirable excipients, and is more expensive than other regimens for most national HIV programmes. The development of low-cost, solid fixed-dose combinations of LPV/r with various nucleoside reverse transcriptase inhibitor (NRTI) backbones in modular unit forms (LPV/ABC/3TC and LPV/ZDV/3TC) is thus greatly needed to improve both management and adherence of children especially in resource-limited settings. Methodology: The pharmacokinetic (PK) analysis combined 25 datasets including therapeutic drug monitoring and published clinical studies from IMPAACT and PENTA. Intensive and sparse PK data totaling 1394 LPV concentrations from 338 subjects, aged 2 days to 24 years old, were analysed. For 3TC, ABC, and ZDV, a total of 927 patients with 3820 concentrations, 188 patients with 1232 concentrations, and 756 patients with 3312 concentrations were used, respectively. Population PK analyses were performed for each drug using MONOLIX 4. Simulations of current dosing recommendations were performed to assess their ability to provide optimal exposure in children weighing 4 to 25 kg. For the NRTIs, dose ratios of 0.375 and 2 were respectively used for 3TC to LPV and ZDV-ABC to 3TC. Results: After allometric scaling, a PK age effect was observed for all drugs. This age effect described increasing apparent clearance for all NRTIs and increasing bioavailability for LPV with age. The simulations indicated that the WHO dosing recommendations resulted in more than 95% of subjects with LPV Cmin > 1.0 mg/L. However, using the recommended drug ratios, the combination dosage for the 4-6 kg weight band (LPV/ZDV: 120/90mg BID) resulted in high ZDV exposure with more than 20% of subjects at levels associated with high risk of neutropenia (Cave>0.8 mg/L). Reducing the LPV/ZDV dosage to 80/60 mg BID dramatically decreased frequency of high ZDV concentrations and risk of neutropenia. This dosage reduction retained LPV Cmin >1.0 mg/L in more than 95% of subjects and did not adversely affect therapeutic target obtainment for the NRTIs. Moreover, this proposed dosage fully corresponded to the WHO guidelines for all NRTIs. Conclusions: These simulations suggest that a pediatric fixed-dose LPV/3TC/ZDV or ABC formulation could be developed to achieve targeted therapeutic levels for all ARV components. Each unit would include 40 mg LPV, 10 mg RTV, 15 mg 3TC and 30 mg ABC or ZDV. According to the weight bands, i.e. 4-6 kg, 6-10 kg, 10-14 kg, 14-20 kg, 20-25 kg, therapeutic doses would be 2, 3, 4, 5, or 6 units twice daily of this formulation.